The use of cardiovascular risk factor information in practice databases: Making the best of patient data

British Journal of General Practice

Volumn 56, Issue 529, 2006, Pages 600-605

  Marshall, Tom ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cardiovascular disease; Cost effectiveness; Patient identification

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; ENALAPRIL; METOPROLOL; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; DRUG EFFICACY; GENERAL PRACTICE; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL INFORMATICS; PATIENT INFORMATION; PRIMARY PREVENTION; RISK FACTOR; UNITED KINGDOM;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DATA COLLECTION; DATABASES AS TOPIC; FAMILY PRACTICE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PRIMARY PREVENTION; RISK FACTORS;

EID: 33747075407     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
2. Wood D, Durrington P, Poulter N, et al. on behalf of the Societies. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl 2): S1-S29.
3. Department of Health. Health Survey for England 1998. The Stationery Office: London, 2000.
4. Marshall T, Rouse A. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ 2002; 325: 197-199.
5. Anderson KM, Odell PM, Silson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
6. Anderson KA, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
7. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 1991; 22: 312-318.
8. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136(2): 161-172.
9. LaRosa JC, He J, Vapputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282(24): 2340-2346.
10. Warshafsky S, Packard D, Marks SJ, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med 1999; 14(12): 763-774.
11. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-1426.
12. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-1432.
13. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126(10): 761-767.
14. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335(8692): 765-774.
15. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-839.
16. Netten A, Curtil L. Unit costs of health and social care 2000. University of Kent at Canterbury: Personal Social Services Research Unit, 2000.
17. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary 48. London: BMA, 2004.
18. Prescription pricing authority. NHS Electronic Drug Tariff 2004. http://www.ppa.org.uk/edt/November_2004/mindex.htm (accessed 29 Jun 2006).
19. The Department of Health. Investing in general practice: the new general medical services contract. Appendix A. London: DoH, 2003. http://www.dh.gov.uk/assetRoot/04/08/27/10/04082710.pdf (accessed 29 Jun 2006).